Genmab A/S – ADR (NASDAQ:GMAB) on Monday shared topline results from the Phase 3 EPCORE DLBCL-4 trial.
The trial evaluated the combination of fixed-duration epcoritamab and lenalidomide, compared to standard-of-care, rituximab plus gemcitabine plus oxaliplatin (R-GemOx), in adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL) who received at least one prior line of treatment.
• Genmab stock is surging to new heights today. Why is GMAB stock up today?
Genmab and AbbVie Inc. (NYSE:ABBV) continue to evaluate epcoritamab as a monotherapy and in combination across lines of therapy in a range of hematologic malignancies.
Phase 3 Trial Meets Primary Progression-Free Survival Goal
